In preclinical ovarian cancer models, trastuzumab‐ and pertuzumab‐based imaging have demonstrated a decrease in HER2 expression following trastuzumab or heat shock protein 90 (HSP90)‐targeted therapy, providing a measurable response [76, 77, 78]. This evidence concerns the gene ERBB2 and ovarian cancer.